ArticleBMC nephrology2025
Combined predictive value of prognostic nutritional index and neutrophil to lymphocyte ratio for all-cause mortality risk in maintenance hemodialysis patients: a cohort study followed for 5 years.
Article in BMC nephrology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Article
- Association of systemic inflammatory response index (SIRI) with clinical outcomes in hemodialysis patients: a single-center observational study.BMC nephrology · 2026Observational
- Association of Neutrophil-to-Lymphocyte Ratio and C-Reactive Protein-to-Albumin Ratio with Renal Anemia in Maintenance Hemodialysis Patients.Pakistan journal of medical sciences · 2026Article
- Association between inflammatory markers and mortality in hemodialysis patients.Jornal brasileiro de nefrologiaArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundTo assess the prognostic value of the prognostic nutritional index (PNI) alongside the neutrophil-to-lymphocyte ratio (NLR) in forecasting all-cause mortality in patients undergoing maintenance hemodialysis (MHD), and to pinpoint independent risk factors linked to all-cause mortality, thereby facilitating the guidance of prompt clinical interventions.
methodsA retrospective cohort investigation was carried out with the gathering of comprehensive demographic and clinical biochemical information. The follow-up period ended in December 2024, with all-cause mortality serving as the primary outcome measure. The predictive capabilities of PNI and NLR regarding all-cause mortality in MHD patients were evaluated through receiver operating characteristic (ROC) curve analysis. In addition to the plotting of Kaplan-Meier curves, the Cox model was utilized to pinpoint risk factors affecting 5-year all-cause mortality in MHD patients.
resultsA sum of 632 patients receiving MHD was analyzed during the follow-up. The area under the curve (AUC) for PNI and NLR was 0.739 and 0.668, with an optimal cutoff value of 43.094 and 2.937, respectively. Furthermore, patients presenting a PNI of ≥ 43.094 showed a better cumulative survival rate throughout the follow-up when compared to those with a PNI of < 43.094 (χ² = 56.461, P < 0.001). In contrast, patients with an NLR of ≥ 2.937 exhibited a diminished cumulative survival rate as opposed to those with an NLR under 2.937 (χ² = 125.414, P < 0.001). The Cox regression model identified male sex, utilization of central venous catheters (CVCs), an NLR of ≥ 2.937, increased absolute neutrophil count, and elevated aspartate aminotransferase (AST) levels for predicting 5-year all-cause mortality independently (P < 0.05). Conversely, a PNI of ≥ 43.094, along with high levels of hemoglobin, urea, and uric acid, were recognized as protective factors (P < 0.05).
conclusionBoth PNI and NLR have significant predictive value concerning all-cause mortality in MHD patients. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.